drugset / Trial / NCT05335018
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Prospective, open-ended, single-arm, multicenter Phase II clinical trial. To evaluate the efficacy of Glofitamab, Poseltinib, and Lenalidomide combination therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Timeline
- Start
- 2022-05-30
- Primary completion
- 2025-11-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | 30 mg | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 20 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 30 mg | Oral |
| Subject | Poseltinib | Unknown | 40 mg | Oral |